KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Payables (2016 - 2025)

Boston Scientific (BSX) has disclosed Payables for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Payables rose 19.17% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 19.17% year-over-year, with the annual reading at $1.1 billion for FY2025, 19.17% up from the prior year.
  • Payables hit $1.1 billion in Q4 2025 for Boston Scientific, up from $1.0 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.1 billion in Q4 2025 to a low of $615.0 million in Q1 2021.
  • Historically, Payables has averaged $865.4 million across 5 years, with a median of $902.5 million in 2023.
  • Biggest five-year swings in Payables: surged 54.78% in 2021 and later decreased 2.37% in 2024.
  • Year by year, Payables stood at $794.0 million in 2021, then rose by 8.56% to $862.0 million in 2022, then grew by 9.28% to $942.0 million in 2023, then grew by 1.91% to $960.0 million in 2024, then grew by 19.17% to $1.1 billion in 2025.
  • Business Quant data shows Payables for BSX at $1.1 billion in Q4 2025, $1.0 billion in Q3 2025, and $962.0 million in Q2 2025.